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than two treatment arms). Twenty-one different interventions were assessed. The interventions were grouped into two categories: immunomodulatory/anti-inflammatory and uncertain. Only one study was assessed as being at low risk of bias. There was insufficient evidence to support or refute the use of any intervention.
Conclusions No single treatment was found to be effective and therefore the results remain inconclusive in regard to the best systemic intervention for RAS. This is likely to reflect the poor methodological rigour of trials, and lack of studies for certain drugs, rather than the true effect of the intervention. It is also recognised that in clinical practice, individual drugs appear to work for individual patients and so the interventions are likely to be complex in nature. In addition, it is acknowledged that systemic interventions are often reserved for those patients who have been unresponsive to topical treatments, and therefore may represent a select group of patients. Overall the individual studies were too different in aspects like timing and outcome measure to allow for any comparison. Adding the limited quality, no recommendation for any agent was possible.
Regardless of the high quality of the review, the modest number of subjects and the restricted length of the included studies limits the ability to identify potential long-term benefits or complications.
Possible interactions with other medications will need to be considered. Potential gaps in the present understanding of RAS may explain the limited efficacy of some modalities.
Despite the results, it is important to note that most of the agents described are drugs or interventions that are not part of the clinician 's everyday armamentarium and as a result may not be adopted even in the presence of more compelling evidence. This paper is based on a Cochrane Review published in the Cochrane Library 2012, issue 9 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Library should be consulted for the most recent version of the review.
Silvia Spivakovsky

Practice point
• No recommendations for the use for any particular systemic agent for the treatment of recurrent aphthous stomatitis (RAS).
